0000899243-20-018277.txt : 20200702 0000899243-20-018277.hdr.sgml : 20200702 20200702161834 ACCESSION NUMBER: 0000899243-20-018277 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200702 DATE AS OF CHANGE: 20200702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tucker John H CENTRAL INDEX KEY: 0001303480 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38293 FILM NUMBER: 201009573 MAIL ADDRESS: STREET 1: INDEVUS PHARMACEUTICALS, INC. STREET 2: 99 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: scPharmaceuticals Inc. CENTRAL INDEX KEY: 0001604950 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465184075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2400 DISTRICT AVENUE STREET 2: SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 617-517-0730 MAIL ADDRESS: STREET 1: 2400 DISTRICT AVENUE STREET 2: SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-30 0 0001604950 scPharmaceuticals Inc. SCPH 0001303480 Tucker John H C/O SCPHARMACEUTICALS INC. 2400 DISTRICT AVENUE, SUITE 310 BURLINGTON MA 01803 1 1 0 0 President and CEO Common Stock 2020-06-30 4 M 0 42250 A 47250 D Common Stock 2020-06-30 4 F 0 10288 7.36 D 36962 D Restricted Stock Units 2020-06-30 4 M 0 42250 0.00 D Common Stock 42250 0 D Stock Option (right to buy) 3.25 2020-06-30 4 A 0 42250 0.00 A 2029-02-25 Common Stock 42250 42250 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units. On February 25, 2019, the Reporting Person was granted 84,500 restricted stock units (the "RSUs"). One half (1/2) of the RSUs shall vest upon the Issuer's submission of a New Drug Application ("NDA") for its product candidate, FUROSCIX and the remaining one half (1/2) shall vest upon the Food & Drug Administration's (the "FDA") approval of the NDA. On June 30, 2020, the performance criteria for the first half of the grant was met and 42,250 shares vested. On February 25, 2019, the Reporting Person was granted an option to purchase 84,500 shares of common stock. One half (1/2) of the shares shall vest upon the Issuer's submission of an NDA for its product candidate, FUROSCIX and the remaining one half (1/2) shall vest upon the FDA's approval of the NDA. On June 30, 2020, the performance criteria for the first half of the grant was met and 42,250 shares vested. /s/ John Tucker 2020-07-02